Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusFRA:AJ8 -3.94%46 Market Cap is €278.1 Mil as of Aug. 18, 2026. GuruFocus rates FRA:AJ8 with a GF Score™ of 46/100 and a GF Value™ of €3.22 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 1,422 Biotechnology companies, Agenus ranks better than 64.06% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Agenus's share price for the quarter that ended in Jun. 2026 was €2.7. Agenus's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 44.8 Mil. Therefore, Agenus's market cap for the quarter that ended in Jun. 2026 was €120.8 Mil.
Agenus's quarterly market cap
increased
from Dec. 2025 (€94.7 Mil) to Mar. 2026 (€110.2 Mil) and
increased
from Mar. 2026 (€110.2 Mil) to Jun. 2026 (€120.8 Mil).
Agenus's annual market cap
declined
from Dec. 2023 (€284.4 Mil) to Dec. 2024 (€62.9 Mil) but then
increased
from Dec. 2024 (€62.9 Mil) to Dec. 2025 (€94.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Agenus's Enterprise Value for Today is €291.2 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Agenus Market Cap Related Terms
Agenus Market Cap Historical Data
* Premium members only.
The historical data trend for Agenus's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agenus's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's Market Cap distribution charts can be found below:
* The bar in red indicates where Agenus's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Agenus's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus (FRA:AJ8) has a Market Cap of €278.1 Mil as of Aug. 18, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Agenus and its competitors. According to the industry distribution chart, Agenus ranks #511 out of 1422 companies in the Biotechnology industry, placing it in the top 35.9%.
Is Agenus' Market Cap too high?
Agenus' current Market Cap is €278.1 Mil. Based on the distribution chart, Agenus ranks #511 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Agenus has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' Market Cap compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #511 out of 1422 companies for Market Cap. This puts Agenus in the upper half of its industry. The industry median Market Cap is 118.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.87, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Agenus and its competitors. For the Biotechnology industry, the median Market Cap is 118.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current Market Cap is €278.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (FRA:AJ8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.22, compared to a current price of €6.10 — trading 89.4% above its estimated fair value. The current Market Cap is €278.1 Mil. Agenus' overall GF Score™ is 46/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Agenus (FRA:AJ8), the current Market Cap is €278.1 Mil as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (FRA:AJ8) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of €6.10 is trading 89.4% above its estimated GF Value™ of €3.22.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for FRA:AJ8:
Market Cap: €278.1 Mil
GF Value™: €3.22 vs. price of €6.10 (89.4% above fair value)
No single metric tells the full story. See the FRA:AJ8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
46GF Score
Get the complete analysis for FRA:AJ8
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AJ8 has been successfully added to your 
